Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.

被引：1
|
作者：
Akce, Mehmet
Alese, Olatunji B.
Shaib, Walid Labib
Wu, Christina Sing-Ying
Lesinski, Gregory B.
El-Rayes, Bassel F.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH USA
[3] Richard J Solove Res Inst, Columbus, OH USA
[4] Emory Univ Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.TPS526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS526
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies
    Hubbard, Joleen M.
    Kim, George
    Borad, Mitesh J.
    Johnson, Elizabeth
    Qin, Rui
    Lensing, Janet
    Puttabasavaiah, Suneetha
    Wright, John
    Erlichman, Charles
    Grothey, Axel
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (01) : 96 - 103
  • [32] Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies
    Joleen M. Hubbard
    George Kim
    Mitesh J. Borad
    Elizabeth Johnson
    Rui Qin
    Janet Lensing
    Suneetha Puttabasavaiah
    John Wright
    Charles Erlichman
    Axel Grothey
    Investigational New Drugs, 2016, 34 : 96 - 103
  • [33] A phase I study of reolysin given intravenously to patients with advanced malignancies.
    Vidal, L.
    Pandha, H.
    Spicer, J.
    Harrington, K. J.
    Allen, S.
    Leader, D.
    Coffey, M.
    Thompson, B.
    Kaye, S.
    De-Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 136S - 136S
  • [34] Phase I study of XL-119, a rebeccamycin analog, in patients with refractory hematological malignancies.
    Giles, Francis J.
    Ravandi, Farhad
    Cortes, Jorge
    Estrov, Zeev
    Fader, Stefan
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Thomas, Deborah
    Wierda, William
    Verstovsek, Srdan
    BLOOD, 2006, 108 (11) : 557A - 557A
  • [35] Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience
    Glitza, I. C.
    Patel, S.
    Zarifa, A.
    Leung, C. H.
    Lin, H.
    McQuinn, L.
    Gong, J.
    Yilmaz, B.
    Chambers, J.
    Sulovic, S.
    John, I.
    Hennegan, T.
    Fu, S.
    Tsimberidou, A. M.
    Janku, F.
    Karp, D. D.
    Meric-Bernstam, F.
    Naing, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S756 - S756
  • [36] A phase 1 study of a novel spectrum selective inhibitor (SSKI), XL880, administered orally in patients with advanced solid malignancies.
    LoRusso, P
    Appleman, L
    Heath, E
    Malburg, L
    Zhu, AX
    Carey, M
    Shapiro, GI
    Eder, JP
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [37] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
    Weiss, Glen J.
    Waypa, Jordan
    Blaydorn, Lisa
    Coats, Jessica
    McGahey, Kayla
    Sangal, Ashish
    Niu, Jiaxin
    Lynch, Cynthia A.
    Farley, John H.
    Khemka, Vivek
    BRITISH JOURNAL OF CANCER, 2017, 117 (01) : 33 - 40
  • [38] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
    Glen J Weiss
    Jordan Waypa
    Lisa Blaydorn
    Jessica Coats
    Kayla McGahey
    Ashish Sangal
    Jiaxin Niu
    Cynthia A Lynch
    John H Farley
    Vivek Khemka
    British Journal of Cancer, 2017, 117 : 33 - 40
  • [39] Phase I trial of AT-101, an orally bioavailable inhibitor of BCL-2, in patients with advanced malignancies.
    Saleh, M
    Pitot, H
    Hartung, J
    Holmlund, J
    LoBuglio, A
    Forero, A
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9121S
  • [40] Preliminary data of phase I clinical trial with autologous cytokine induced killer cells in patients with advanced malignancies.
    Olioso, P
    Giancola, R
    Di Riti, M
    Accorsi, P
    Angrilli, F
    Spadano, A
    Di Bartolomeo, P
    Fioritoni, GI
    D'Antonio, D
    Iacone, A
    BLOOD, 2003, 102 (11) : 57B - 58B
12345